CHICAGO — Andrew Krivoshik, MD, PhD, senior vice president and oncology therapeutic area head at Astellas Pharma, spoke with HemOnc Today at ASCO Annual Meeting about key data presented this year.
He discussed the EV-201 study, which showed the investigational therapy enfortumab vedotin induced objective response among 44% of patients with locally advanced or metastatic urothelial cancer whose disease progressed after two prior lines of therapy.
“That is really impactful for patients and really highlights why we do what we do, which is to try to address areas of high unmet need and patients who have very difficult-to-treat tumors,” Krivoshik said.
Krivoshik also provided an overview of the company’s oncology pipeline.
“Not only do we continue to move our agents that are already approved for more advanced disease states earlier in the disease continuum, we have a number of other late-stage agents that continue to progress,” Krivoshik said. – by Mark Leiser
Reference: Petrylak DP, et al. Abstract. LBA4505. Presented at: ASCO Annual Meeting; May 31-June 4, 2019; Chicago.